Darin Lippoldt net worth and biography

Darin Lippoldt Biography and Net Worth

Darin M. Lippoldt J.D. serves as Chief Legal Officer and Corporate Secretary of the Company. He was appointed Chief Legal Officer and Corporate Secretary in October 2014 and has oversight of all corporate legal matters, intellectual property, and corporate compliance. Prior to joining Neurocrine Biosciences, Mr. Lippoldt served as Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary of Volcano Corporation, a company he joined in 2010. Prior to Volcano, Mr. Lippoldt served as Associate General Counsel at Amylin Pharmaceuticals, Inc. since 2003. He previously practiced corporate and securities law with the law firms of Fulbright & Jaworski LLP and Matthews and Branscomb, P.C. Mr. Lippoldt received a B.B.A. in Finance, an M.A. in International Relations and a J.D. from St. Mary’s University.

What is Darin Lippoldt's net worth?

The estimated net worth of Darin Lippoldt is at least $3.10 million as of November 3rd, 2022. Mr. Lippoldt owns 29,234 shares of Neurocrine Biosciences stock worth more than $3,095,588 as of February 6th. This net worth approximation does not reflect any other assets that Mr. Lippoldt may own. Learn More about Darin Lippoldt's net worth.

How do I contact Darin Lippoldt?

The corporate mailing address for Mr. Lippoldt and other Neurocrine Biosciences executives is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. Neurocrine Biosciences can also be reached via phone at (858) 617-7600 and via email at [email protected] Learn More on Darin Lippoldt's contact information.

Has Darin Lippoldt been buying or selling shares of Neurocrine Biosciences?

Darin Lippoldt has not been actively trading shares of Neurocrine Biosciences during the last ninety days. Most recently, Darin Lippoldt sold 4,518 shares of the business's stock in a transaction on Thursday, November 3rd. The shares were sold at an average price of $125.02, for a transaction totalling $564,840.36. Following the completion of the sale, the insider now directly owns 29,234 shares of the company's stock, valued at $3,654,834.68. Learn More on Darin Lippoldt's trading history.

Who are Neurocrine Biosciences' active insiders?

Neurocrine Biosciences' insider roster includes Matt Abernethy (CFO), Eric Benevich (Insider), David Boyer (Insider), Julie Cooke (Insider), Kyle Gano (Insider), Kevin Gorman (CEO), Dimitri Grigoriadis (Insider), Darin Lippoldt (Insider), Malcolm Lloyd-Smith (Insider), Gary Lyons (Director), Richard Pops (Director), William Rastetter (Director), Eiry Roberts (Insider), and Stephen Sherwin (Director). Learn More on Neurocrine Biosciences' active insiders.

Are insiders buying or selling shares of Neurocrine Biosciences?

During the last year, insiders at the sold shares 25 times. They sold a total of 240,408 shares worth more than $26,648,034.37. The most recent insider tranaction occured on January, 31st when insider Eiry Roberts sold 1,457 shares worth more than $160,255.43. Insiders at Neurocrine Biosciences own 4.4% of the company. Learn More about insider trades at Neurocrine Biosciences.

Information on this page was last updated on 1/31/2023.

Darin Lippoldt Insider Trading History at Neurocrine Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/3/2022Sell4,518$125.02$564,840.3629,234View SEC Filing Icon  
11/1/2022Sell10,000$120.09$1,200,900.0029,234View SEC Filing Icon  
10/27/2022Sell4,923$115.04$566,341.9229,234View SEC Filing Icon  
3/22/2022Sell8,455$95.05$803,647.75View SEC Filing Icon  
3/18/2022Sell300$95.00$28,500.00View SEC Filing Icon  
7/9/2020Sell1,657$136.02$225,385.1427,678View SEC Filing Icon  
5/18/2020Sell5,000$120.00$600,000.0031,021View SEC Filing Icon  
11/8/2019Sell10,000$110.01$1,100,100.0026,728View SEC Filing Icon  
9/3/2019Sell6,736$100.00$673,600.00View SEC Filing Icon  
8/27/2019Sell3,264$100.05$326,563.2021,625View SEC Filing Icon  
8/23/2019Sell1,664$100.09$166,549.7621,625View SEC Filing Icon  
7/30/2019Sell15,831$92.13$1,458,510.03160,732View SEC Filing Icon  
1/3/2018Sell1,979$79.36$157,053.44View SEC Filing Icon  
12/28/2017Sell15,237$75.00$1,142,775.00View SEC Filing Icon  
12/28/2017Sell15,237$75.00$1,142,775.0028,394View SEC Filing Icon  
12/8/2017Sell2,955$75.00$221,625.0016,112View SEC Filing Icon  
12/4/2017Sell6,279$75.04$471,176.1619,436View SEC Filing Icon  
11/15/2017Sell9,900$73.05$723,195.00View SEC Filing Icon  
11/9/2015Sell23,761$52.92$1,257,432.12View SEC Filing Icon  
See Full Table

Darin Lippoldt Buying and Selling Activity at Neurocrine Biosciences

This chart shows Darin Lippoldt's buying and selling at Neurocrine Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Neurocrine Biosciences Company Overview

Neurocrine Biosciences logo
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm's product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $105.02
Low: $104.22
High: $110.87

50 Day Range

MA: $116.14
Low: $107.99
High: $127.06

2 Week Range

Now: $105.02
Low: $75.25
High: $129.29

Volume

1,579,363 shs

Average Volume

929,319 shs

Market Capitalization

$10.10 billion

P/E Ratio

184.25

Dividend Yield

N/A

Beta

0.49